410 related articles for article (PubMed ID: 20946660)
1. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
2. Anti-PrP
Cox TO; Gunther EC; Brody AH; Chiasseu MT; Stoner A; Smith LM; Haas LT; Hammersley J; Rees G; Dosanjh B; Groves M; Gardener M; Dobson C; Vaughan T; Chessell I; Billinton A; Strittmatter SM
Ann Clin Transl Neurol; 2019 Mar; 6(3):554-574. PubMed ID: 30911579
[TBL] [Abstract][Full Text] [Related]
3. Anti-PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease.
Li R; Ren M; Yu Y
Brain Behav; 2021 Nov; 11(11):e2365. PubMed ID: 34672433
[TBL] [Abstract][Full Text] [Related]
4. Impairment of Spike-Timing-Dependent Plasticity at Schaffer Collateral-CA1 Synapses in Adult APP/PS1 Mice Depends on Proximity of Aβ Plaques.
Garad M; Edelmann E; Leßmann V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573114
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
6. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
7. Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
Purro SA; Farmer M; Noble E; Sarell CJ; Powell M; Yip D; Giggins L; Zakka L; Thomas DX; Farrow M; Nicoll AJ; Walsh D; Collinge J
PLoS One; 2023; 18(11):e0294465. PubMed ID: 37976283
[TBL] [Abstract][Full Text] [Related]
8. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
[TBL] [Abstract][Full Text] [Related]
9. Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice.
Umeda T; Tomiyama T; Kitajima E; Idomoto T; Nomura S; Lambert MP; Klein WL; Mori H
Life Sci; 2012 Dec; 91(23-24):1169-76. PubMed ID: 22273754
[TBL] [Abstract][Full Text] [Related]
10. In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP(SW) and APP(SW)/PS1(L166P) Alzheimer's transgenic mice.
Duszczyk M; Kuszczyk M; Guridi M; Lazarewicz JW; Sadowski MJ
Neurochem Int; 2012 Dec; 61(7):976-80. PubMed ID: 22841892
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice.
Xiao S; Song LL; Li JT; Wang H; Yu N; Wang ZQ; Zhang Y; He JS; Hung T
J Alzheimers Dis; 2020; 73(2):657-670. PubMed ID: 31839610
[TBL] [Abstract][Full Text] [Related]
12. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
Cai Z; Wang C; He W; Chen Y
Curr Alzheimer Res; 2018; 15(11):1045-1052. PubMed ID: 29962345
[TBL] [Abstract][Full Text] [Related]
13. Fruitless Wolfberry-Sprout Extract Rescued Cognitive Deficits and Attenuated Neuropathology in Alzheimer's Disease Transgenic Mice.
Liu SY; Lu S; Yu XL; Yang SG; Liu W; Liu XM; Wang SW; Zhu J; Ji M; Liu DQ; Zhang ZP; Liu RT
Curr Alzheimer Res; 2018; 15(9):856-868. PubMed ID: 29623840
[TBL] [Abstract][Full Text] [Related]
14. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Yang RY; Zhao G; Wang DM; Pang XC; Wang SB; Fang JS; Li C; Liu AL; Wu S; Du GH
Pharmacol Biochem Behav; 2015 Dec; 139(Pt A):15-26. PubMed ID: 26476132
[TBL] [Abstract][Full Text] [Related]
15. Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.
Huang H; Nie S; Cao M; Marshall C; Gao J; Xiao N; Hu G; Xiao M
Age (Dordr); 2016 Aug; 38(4):303-322. PubMed ID: 27439903
[TBL] [Abstract][Full Text] [Related]
16. Huatuo Zaizao pill ameliorates cognitive impairment of APP/PS1 transgenic mice by improving synaptic plasticity and reducing Aβ deposition.
Zhang JH; Yu LJ; Yang H; Hui Z; Jiang S; Chen L; Zhao Y; Wang SL; Liu Y; Xu Y
BMC Complement Altern Med; 2018 May; 18(1):167. PubMed ID: 29843688
[TBL] [Abstract][Full Text] [Related]
17. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease.
Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS
Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065
[TBL] [Abstract][Full Text] [Related]
18. Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates Aβ pathology and improves cognitive function.
Kim TK; Han HE; Kim H; Lee JE; Choi D; Park WJ; Han PL
Exp Mol Med; 2012 Dec; 44(12):740-8. PubMed ID: 23172351
[TBL] [Abstract][Full Text] [Related]
19. Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice.
Liu D; Zhao Y; Qi Y; Gao Y; Tu D; Wang Y; Gao HM; Zhou H
J Neuroinflammation; 2020 Aug; 17(1):258. PubMed ID: 32867800
[TBL] [Abstract][Full Text] [Related]
20. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
